Prot # VX-950-C211: A Randomized, Open-Label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination with Pegylated Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C Virus Infect

Project: Research project

Project Details

Effective start/end date3/16/118/31/13


  • Tibotec Pharmaceuticals Ltd. (Prot # VX-950-C211)